Immix Biopharma (NASDAQ:IMMX) Announces Earnings Results

Immix Biopharma (NASDAQ:IMMX) announced its quarterly earnings results on Thursday. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.01), FiscalAI reports.

Immix Biopharma Trading Down 6.8%

Shares of NASDAQ:IMMX traded down $0.59 during trading on Thursday, reaching $8.07. The company’s stock had a trading volume of 959,607 shares, compared to its average volume of 1,235,955. Immix Biopharma has a 12 month low of $3.45 and a 12 month high of $15.10. The firm’s 50 day simple moving average is $9.94 and its two-hundred day simple moving average is $9.57. The stock has a market capitalization of $577.33 million, a PE ratio of -9.17 and a beta of 0.29.

Wall Street Analyst Weigh In

IMMX has been the subject of a number of research analyst reports. Mizuho set a $23.00 price objective on Immix Biopharma in a research report on Thursday, October 29th. Citigroup reiterated a “market outperform” rating on shares of Immix Biopharma in a research report on Wednesday, September 30th. Morgan Stanley reissued an “overweight” rating on shares of Immix Biopharma in a research note on Tuesday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, October 15th. Finally, HC Wainwright upped their price objective on Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Immix Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.86.

Immix Biopharma Company Profile

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.